Disclosures: Vaclav Smid: Nothing to Disclose, Ksenyia Dryahina: Nothing to Disclose, Barbora Novkov: Nothing to Disclose, Stefan Swift: Nothing to Disclose, Simon Dostal: Nothing to Disclose, Sarka Svobodova: Nothing to Disclose, Martin Lenicek: Nothing to Disclose, Patrik Spanel: Nothing to Disclose, Radan Bruha: Nothing to Disclose 855 BASELINE CHARACTERISTICS IN WELL-COMPENSATED NASH CIRRHOSIS PATIENTS DIAGNOSED WITH OR WITHOUT A LIVER BIOPSY IN MAESTRO-NASH-OUTCOMES, A CLINICAL OUTCOME PHASE 3 STUDY ASSESSING THE EFFECT OF RESMETIROM IN WELL COMPENSATED NASH CIRRHOSIS Meena Bansal 1 Jrn Schattenberg 2 Kris Kowdley 3 Mazen Noureddin 4 Rohit Loomba 5 Rebecca Taub 6 Dominic Labriola 6 David Schneider 6 , 1 Icahn School of Medicine at Mount Sinai (ISMMS), 2 Saarland University Medical Center, Homburg and Saarland University, 3 Liver Institute Northwest, 4 Houston Methodist Hospital, 5 University of California, San Diego, 6 Madrigal Pharmaceuticals Background: MAESTRO- NASH Outcomes (NCT05500222) is a multi-national, multicenter, double-blind, randomized, placebo-controlled study in well-compensated NASH cirrhosis
The Role of the Nutritionist in Clinical Management
If youre looking for the same B vitamins in tablet form, see Neurobion B1 B6 B12 tablets, our Methycobal B12 500 mcg tablets, or our multivitamin range
No human clinical trials have been published
The product is intended for multidose use and has been developed under strict quality control in Sweden
